Tamiflu Adverse Drug Reactions [ADR] and Neurological Effects
Sold under the name generic tamiflu, Oseltamivir is available in capsules of oseltamivir phosphate 98.5 mg equivalent to oseltamivir 75 mg. and in powder form for taking the medication by mouth of oseltamivir phosphate equivalent to oseltamivir 12 mg/ml. There are some common adverse reactions to the generic tamiflu, which were found occurring in over one percent of those who partook in the study, they included vomiting and diarrhea, nausea stomach discomfort and headache. More uncommon side effects were hepatitis and increased liver enzymes, rash, allergic outcomes including anaphylactic shock and Stevens-Johnson syndrome. Certain other unfavorable reactions were reported during after marketing surveys like toxic epidermal necrolysis, irregular heartbeat, seizure, confusion, diabetes irritation as well as bloody diarrhea.
There is some unease about whether oseltamivir causes harmful, neuropsychiatric reactions such as some users hurting themselves. This kind of perilous behavior seems to occur more frequently in kids than it does in adults. In Japan where oseltamivir is dispensed most frequently, taking sixty percent of the total global amounts manufactured, the attention has been centered on the youth however, and problems have been found in both adults and kids alike.
In the Spring of 2007, Japan’s Ministry of health cautioned oseltamivir ought not be prescribed to anyone between the ages of ten and nineteen. This same government agency determined prior to this, in may, 2004, to convert all associated reading materials dispensed with oseltamivir must contain neurological and psychological conditions as potential adverse reactions. These included impaired consciousness, atypical conduct and illusion.
According to ministry of health numbers in Japan, from 2004 to spring of 2006, there were fifteen people between the age of ten and nineteen that had been hurt or fatally injured from jumping or falling off of buildings. These happened subsequent to ingesting oseltamivir and a seventeen year old youth in particular had passed away after stepping in front of a truck. Further research of these Japanese statistics was concluded in April, 2007. This advanced study showed that one hundred twenty eight oseltamivir users stated that they had acted in an unusual manner after ingesting oseltamivir since 2001. Forty three of these people where under the age of ten, fifty seven of them were between ten and nineteen years old and twenty eight people were over the age of twenty. In total, eight of these people – five teens and three adult – had perished from their actions.
In the fall of 2006, a children’s doctor responsible for research at a prestigious medical university released some findings based on research of some twenty eight hundred kids that showed no abnormal behavior in those who consumed oseltamivir and those who did not. A certain media source suggested that Chugai Pharmaceutical Company, responsible for generic tamiflu in Japan, donated 10 million yen [or roughly $105,000.00 USD] to this doctor’s facility throughout a five year span.
As a means of determining whether the 2007 ban should be waived, a research group from the Ministry of Health, Labour and Welfare conducted their own study of ten thousand youth under the age of eighteen that had been confirmed as having had the influenza virus from 2006. The study concluded in April of 2009. Understanding and crediting different levels of unusual actions, included were simple behavior problems like incomprehensible speech, researchers discovered that in the kids who consumed the generic tamiflu, fifty four percent were inclined to display atypical behavior than the ones that did not ingest the medication. When the researchers narrowed their scrutiny to those kids who showed grave atypical actions that ended with serious injury or fatality, they discovered that participants who had consumed oseltamivir were twenty five percent more inclined to act or behave more strangely.
In the late fall of 2006 the U.S. Food and Drug Administration [or FDA] modified cautionary messages on the drug packaging to include the potential for adverse reactions such as delirium, hallucinations and other atypical behavior. The FDA’s change to a more thorough and concise advisory warning message from anything previous was based on more evidence than what previously existed regarding an underlying connection between oseltamivir consumption and twelve Japanese children passing away. Current information now showed that one hundred three new complaints submitted to the FDA of delirium, hallucinations and other specific and odd behavior, among Japanese users for the most part, between August, 2005 and July, 2006. This number was on top of the one hundred twenty six claims made on oseltamivir from its first appearance on the market in 1999 and August 2005.
The producer Roche argues that Tamiflu treatments number fifty million people since its inception in 1999, and notes that the influenza virus on its own is responsible for causing some troubling psychological effects.
Closer monitoring by the European Medicines Agency is now in effect based on a statement made in the spring of 2007 claiming that oseltamivir benefits prevailed over the costs though they would keep a close eye on Japanese studies.
Also in spring, 2007 South Korea released a cautionary warning not to dispense tamiflu to teenagers unless it was under exceptional circumstances.